Login to Your Account

Adventrx's CoFactor OK'd For Phase III In Colorectal Cancer

By Randall Osborne

Tuesday, April 26, 2005
A week after presenting positive data from an ongoing Phase II trial with CoFactor, its biomodulator to enhance 5-FU in treatment regimens for metastatic colorectal cancer, Adventrx Pharmaceuticals Inc. said the FDA cleared the way to start a Phase III pivotal trial under a special protocol assessment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription